Clinical Trial Update: A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [NA]

View source ↗

Summary

An ongoing clinical trial is evaluating the combination of iparomlimab and tuvonralimab, with or without chemotherapy, for second-line and subsequent treatment …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Tuvonralimab (tuvonralimab)
• iparomlimab

Snippet

Sponsor: The Second Affiliated Hospital of Hainan Medical University | Conditions: Squamous Cell Carcinoma of Head and Neck | NA | Status: RECRUITING